SZN-8141 — Initial data
H2 2027
First patient dosing is expected in the fourth quarter of 2026, with initial data expected in the second half of 2027.Source filing
SRZN biotech catalysts & pipeline
SURROZEN INC · Data as of 2026-10-25
catalyst calendar
/